The Role of Vitamin D Supplements on Pulmonary Hypertension in Patients with Thalassemia

Evaluation of the Role of Vitamin D Supplements on Pulmonary Hypertension in Patients with Thalassemia Major and Intermedia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190206042644N1

Enrollment

Registered

2019-03-11

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Pulmonary Hypertension. Condition 2: Thalassemia. Primary pulmonary hypertension Beta thalassemia

Interventions

Intervention 1: Intervention group: Individuals in this Group are treated with Oral Vitamin D, at a dose of 500,000 units per week, for 20 weeks. Intervention 2: Control group: People in this Group wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Parental Informed Consent Patients with Thalassemia Major under Regular Transfusion and Regular Chelation. Patients with Thalassemia Intermedia who do not have Regular Transfusion.

Exclusion criteria

Exclusion criteria: Parental Dissatisfaction for Participation in the Study Congenital and Non-congenital Heart Disease Endocrine Disease such as Diabetes, Hypoparathyroidism and Hypothyroidism

Design outcomes

Primary

Measure	Time frame
Pulmonary Hypertension. Timepoint: Measurement of Pulmonary Arterial Pressure at the Beginning of the Study (After Entering the Study and Before the Onset of the Intervention) and Repeat Measurements 6 months after Entry into the Study. Method of measurement: Echocardiography by Echocardiologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Fadayi

Arak University of Medical Sciences

shaqayeqfadayi@gmail.com+98 26 3420 4232

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026